Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody

References

• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386–2393
   PubMed Web of Science ®Google Scholar
• McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009;23:1163–1175
   PubMed Web of Science ®Google Scholar
• Hou M, Stockelberg D, Kutti J, Wadenvik H. Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 1995;55:307–314
   PubMed Web of Science ®Google Scholar
• Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, Xu RR, Guo CS, Wang XM, Cheng YF, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: A multicenter cohort study. J Thromb haemost 2014;12:497–504
   PubMed Web of Science ®Google Scholar
• Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006;108:943–946
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, Li C, van der Wal DE, Chen P, Spring CM, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012;87:206–208
   PubMed Web of Science ®Google Scholar
• Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet desialyation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 2014;99:e61–e63
   PubMed Web of Science ®Google Scholar
• van der wal DE, Zhu G, Li J, Vadasz B, Yougbare I, Lang S, Freedman J, Ni H. Desialylation: A novel platelet clearance mechanism and a potential new therapeutic target in anti-GPIb antibody mediated thrombocytopenia. Blood (ASH Annual Meeting Abstracts) 2012;120:265
   Google Scholar
• van der wal DE, Li J, Zhu G, Vadasz B, Ma L, Yougbare I, Lang S, Freedman J, Ni H. Anti-GPIb antibody induces platelet desialylation: A novel mechanism of Fc-independent immune thrombocytopenia and a potential new diagnosis and therapy against refractory ITP. Journal of the International Society on Thrombosis and Haemostasis 2013;11(Suppl 2):204
   Google Scholar
• Li CY, Yu Q, Ye ZQ, Sun Y, He Q, Li XM, Zhang W, Luo J, Gu X, Zheng X, Wei L. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 2007;17:357–362
   PubMed Web of Science ®Google Scholar
• Moore ML, Chi MH, Zhou W, Goleniewska K, O'Neal JF, Higginbotham JN, Peebles RSJr. Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol 2007;178:2651–2654
   PubMed Web of Science ®Google Scholar
• Alioglu B, Tasar A, Ozen C, Selver B, Dallar Y. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: A case report. Pathophysiol Haemost Thromb 2010;37:55–58
   PubMedGoogle Scholar
• Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, Ji X, Wang X, Zhang M. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353–357
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg LJr. Crowther MA, American Society of H. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–4207
   PubMed Web of Science ®Google Scholar
• Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008;14:648–655
   PubMed Web of Science ®Google Scholar
• Rumjantseva V, Grewal PK, Wandall HH, Josefsson EC, Sorensen AL, Larson G, Marth JD, Hartwig JH, Hoffmeister KM. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009;15:1273–1280
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000;96:2520–2527
   PubMed Web of Science ®Google Scholar
• Li J, van der Wal DE, Zhu L, Vadasz B, Simpson EK, Li C, Webster ML, Zhu G, Lang S, Chen P, et al. Fc-independent phagocytosis: Implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2013;13:50–58
   PubMedGoogle Scholar